A Schult, H Eriksson… - Scandinavian Journal …, 2011 - informahealthcare.com The exact prevalence is unknown but NAFLD may be present in about 20% of the general population in Europe [11]. It is substantially higher in obese subjects with prevalence figures above 50% [11]. Some patients with NAFLD will develop cirrhosis and end-stage liver disease ... Cited by 2 - Related articles - All 3 versions
D Roulot, JL Costes, JF Buyck, U Warzocha… - Gut, 2011 - gut.bmj.com Results 168 subjects were not considered for analysis due to missing data (n=23), LSM failure (n=51) or unreliable LSM values (n=94). Among the 1190 remaining subjects, 89 (7.5%) had LSM >8 kPa including nine patients with LSM >13 kPa. Despite the fact that normal liver ... Cited by 2 - Related articles - All 3 versions
P Carmeliet, I Colle… - US Patent 7,867,490, 2011 - Google Patents Illllllllllllllllllllllllllllllllllllllllllllllli US007867490B2 (12) United States Patent ao) Patent no.: us 7,867,490 B2 Carmeliet et al. (45) Date of Patent: Jan. 11,2011 (54) TREATMENT OF LIVER CIRRHOSIS AND ITS COMPLICATIONS (75) Inventors: Peter Carmeliet, Blanden (BE); Isabelle Colle, ... Related articles - All 4 versions
J Wanninger, R Wiest, S Bauer… - European journal of …, 2011 - journals.lww.com Objective: Transforming growth factor-[beta]1 (TGF[beta]1) is a short-lived immune suppressive and profibrotic protein. Itslatent precursor is relatively stable and may even protect from fibrosis. Latent TGF[beta]1 is synthesized by various tissues including the liver and portal, ... Related articles - All 5 versions
SW Hong, JE Choi… - 대한간학회지, 2011 - papersearch.net 4Department of Internal Medicine, Aju University College of Medicine, 5Liver Cirrhosis Clinical Research Center, Yonsei University College of Medicine Background: There have been concerns about whether biomarkers measured in the peripheral vein (PV) reflect the dynamic ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
